INT258062

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.11
First Reported 2008
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 2
Disease Relevance 1.05
Pain Relevance 0

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell proliferation (E2F1) nucleoplasm (E2F1) mitochondrion (E2F1)
nucleus (E2F1) DNA binding (E2F1) transcription factor binding (E2F1)
E2F1 (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 74 5.00 Very Low Very Low Very Low
Inflammation 22 5.00 Very Low Very Low Very Low
local anesthetic 22 5.00 Very Low Very Low Very Low
Bioavailability 18 5.00 Very Low Very Low Very Low
agonist 18 5.00 Very Low Very Low Very Low
Angina 14 5.00 Very Low Very Low Very Low
gABA 10 5.00 Very Low Very Low Very Low
Calcium channel 8 5.00 Very Low Very Low Very Low
fibrosis 8 5.00 Very Low Very Low Very Low
headache 8 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Hyperlipidemia 2 80.16 Quite High
Apoptosis 72 79.32 Quite High
Cancer 262 67.68 Quite High
Metastasis 10 64.64 Quite High
Adhesions 6 62.40 Quite High
Breast Cancer 34 49.04 Quite Low
Skin Cancer 8 37.60 Quite Low
Hematologic Neoplasms 2 36.80 Quite Low
Prostate Cancer 22 34.16 Quite Low
Leukemia 6 28.60 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
It has been observed that proteasome inhibitors partially prevent lovastatin-induced E2F-1 degradation, suggesting that lovastatin modulates E2F-1 proteasomal degradation, which may be a critical regulatory mechanism of lovastatin-induced effects [338], and that mevastatin inhibits cdk2 activity in PC3 cells through Thr-160 phosphorylation inhibition of cdk2 [339].
Protein_catabolism (degradation) of E2F-1
1) Confidence 0.11 Published 2008 Journal Mol Cancer Section Body Doc Link PMC2615789 Disease Relevance 0.53 Pain Relevance 0
It has been observed that proteasome inhibitors partially prevent lovastatin-induced E2F-1 degradation, suggesting that lovastatin modulates E2F-1 proteasomal degradation, which may be a critical regulatory mechanism of lovastatin-induced effects [338], and that mevastatin inhibits cdk2 activity in PC3 cells through Thr-160 phosphorylation inhibition of cdk2 [339].
Protein_catabolism (degradation) of E2F-1
2) Confidence 0.11 Published 2008 Journal Mol Cancer Section Body Doc Link PMC2615789 Disease Relevance 0.52 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox